Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
IBA SA : IBA and Elekta enter an MOU regarding a comprehensive partnership including joint software development and sales to advance proton therapy treatments | ||
By: Nasdaq / GlobeNewswire - 23 Sep 2017 | Back to overview list |
|
IBA and Elekta enter an MOU regarding a comprehensive partnership including joint software development and sales to advance proton therapy treatments SAN DIEGO, September 23, 2017 - IBA (Ion Beam Applications) and Elekta (EKTA-B.ST) announced today that they have entered a Memorandum of Understanding (MOU) to agree to work closely together in software development as well as the sales and marketing of each other's products. The announcement was made at the occasion of the American Society for Radiation Oncology (ASTRO) Annual Meeting, which is taking place September 24-27 in San Diego. The companies intend to co-invest in developing new functionality for proton therapy treatment in Elekta's Monaco ® treatment planning system and MOSAIQ ® oncology information system. The purpose is to offer a more seamless experience for comprehensive radiotherapy departments and further improve patient care. In addition to the software development collaboration, both companies expect to offer a joint portfolio of radiation therapy solutions and co-market each other's products, based on a shared vision of integration and adaptive radiation therapy. Richard Hausmann, President and CEO of Elekta, says: "We believe that proton therapy is an important tool in radiation treatment for specific indications and we are very pleased to partner with IBA, the global leader in proton therapy, to further integrate their products into our software solutions." Olivier Legrain, IBA CEO, adds: "Elekta has always been a pioneer in the field of radiation therapy. Our culture of innovation and collaboration fits well with Elekta and we are excited to join forces based on a shared vision of integration." ***ENDS***
About IBA
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
About Elekta
For further information, please contact:
Elekta
IBA
Bernard Dandoy; Investor Relations
Consilium Strategic Communications
Amber Fennell, Matthew Neal, Ivar Milligan
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: IBA SA via GlobeNewswire
HUG#2136361
|
||
|
||
Copyright 2017 Nasdaq / GlobeNewswire | Back to overview list |